SHAREHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of fair value for options granted

	Six Months Ended June 30,
	2025			2024
Expected volatility		104.5	%		-
Risk-free rate		4.2	%		-
Dividend yield		-			-
Expected term (in years)		6.75			-
Share price	$	1.23			-

Schedule of employee and non-employee shares options activity

	Number			Weighted average exercise price		Weighted average remaining contractual life (years)		Aggregate intrinsic value (in thousands)
Options outstanding as of December 31, 2024		4,573		$	187.94		3.47	$	-
Granted		400,000		$	1.23		9.93		-
Exercised		-			-		-		-
Forfeited		(22	)		500.74		-		-
Options outstanding as of June 30, 2025		404,551		$	3.31		9.85	$	-

Options exercisable as of June 30, 2025		4,551		$	186.43		2.99	$	-

Schedule of employee and non-employee RSUs activity

	Number of shares underlying outstanding RSUs			Weighted- average grant date fair value
Unvested RSUs as of December 31, 2024		327,243		$	5.68
Granted		-			-
Vested		(68,286	)		5.84
Forfeited		(25,629	)		4.96
Unvested RSUs as of June 30, 2025		233,328		$	5.72

Schedule of options and RSUs outstanding

Range of exercise price		Options and RSUs outstanding as of June 30, 2025		Weighted average remaining contractual life (years) (1)		Options outstanding and exercisable as of June 30, 2025		Weighted average remaining contractual life (years) (1)
RSUs only			233,328		-		-		-
$	1.2		400,000		9.93		-		-
$	37.6		1,774		3.74		1,774		3.74
$	178.5 - $236.3		1,828		2.85		1,828		2.85
$	350 - $367.5		864		1.96		864		1.96
$	1,277.5 - $3,634.8		85		0.51		85		0.51
			637,879		9.85		4,551		2.99

(1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Schedule of non-cash share-based compensation expense

	Six Months Ended June 30,
	2025		2024
Cost of revenues	$	7	$	9
Research and development, net		73		92
Sales and marketing		138		218
General and administrative		184		438
Total	$	402	$	757

Schedule of warrants outstanding and exercisable

Issuance date	Warrants outstanding		Exercise price per warrant		Warrants outstanding and exercisable		Contractual term
	(number)				(number)
December 31, 2015 (1)		681	$	52.50		681	See footnote (1)
December 28, 2016 (2)		272	$	52.50		272	See footnote (1)
July 6, 2020 (3)		64,099	$	12.32		64,099	January 2, 2026
July 6, 2020 (4)		42,326	$	15.95		42,326	July 2, 2025
December 8, 2020 (5)		83,821	$	9.38		83,821	June 8, 2026
December 8, 2020 (6)		15,543	$	12.55		15,543	June 8, 2026
February 26, 2021 (7)		780,095	$	25.20		780,095	August 26, 2026
February 26, 2021 (8)		93,612	$	32.05		93,612	August 26, 2026
September 29, 2021 (9)		1,143,821	$	14.00		1,143,821	March 29, 2027
September 29, 2021 (10)		137,257	$	17.81		137,257	September 27, 2026
January 8, 2025 (11)		1,818,183	$	2.75		1,818,183	January 10, 2028
January 8, 2025 (12)		109,091	$	3.44		109,091	January 10, 2028
June 26, 2025 (13)		4,000,000	$	0.65		4,000,000	June 26, 2030
June 26, 2025 (14)		240,000	$	0.81		240,000	June 25, 2030
		8,528,801				8,528,801

(1)

Represents warrants for ordinary shares issuable upon an exercise price of $52.50 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or

(ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of June 30, 2025.

(2)

Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.

(3)

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in July 2020. As of June 30, 2025, 288,634 warrants were exercised for a total consideration of $3,556,976. During the six months that ended June 30, 2025, no warrants were exercised.

(4)

Represents warrants that were issued to the placement agent as compensation for his role in the Company’s July 2020 registered direct offering.

(5)

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of June 30, 2025, 514,010 warrants were exercised for a total consideration of $4,821,416. During the six months that ended June 30, 2025, no warrants were exercised.

(6)

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of June 30, 2025, 32,283 warrants were exercised for a total consideration of $405,003. During the six months that ended June 30, 2025, no warrants were exercised.

(7)

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.

(8)

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.

(9)

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.

(10)

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

(11)

Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in January 2025.

(12)

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s January 2025 registered direct offering.

(13)

Represents warrants that were issued to certain institutional investors in connection with the Company’s public offering of ordinary shares in June 2025.

(14)

Represents warrants that were issued to the placement agent as compensation for its role in the Company’s public offering of ordinary shares in June 2025.